Boston Scientific (NYSE:BSX) Reaches New 12-Month Low – What’s Next?

Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low during trading on Wednesday . The stock traded as low as $51.46 and last traded at $50.8310, with a volume of 6969715 shares traded. The stock had previously closed at $57.64.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Unusually heavy call-option buying suggests some traders are positioning for a rebound in Boston Scientific shares. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)
• Positive Sentiment: Boston Scientific continues to advance clinical programs, including the FARAPULSE PFA study and a pain-related diabetic neuropathy trial, which supports its longer-term product pipeline. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: The company also announced progress toward an important data milestone in its painful diabetic neuropathy study, reinforcing its innovation story. Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
• Neutral Sentiment: Wells Fargo cut Boston Scientific to hold from strong-buy and set a $55 target, which still implies modest upside but signals less conviction from analysts. Zacks.com coverage of Wells Fargo downgrade
• Neutral Sentiment: Despite the recent selloff, consensus broker ratings remain broadly constructive, with many analysts still calling BSX a moderate buy.
• Negative Sentiment: Management said sales for a key product line are likely to be flat this quarter and next, underscoring a slowdown in the near-term growth outlook. Why Boston Scientific Stock Was Sliding This Week
• Negative Sentiment: Wells Fargo also downgraded BSX from equal weight/overweight-type bullish stance to equal weight/hold amid concerns about WATCHMAN demand and electrophysiology growth. Wells Fargo cuts Boston Scientific to Equal Weight on Watchman slowdown
• Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, and other coverage pointed to a 52-week low on WATCHMAN headwinds. Boston Scientific hits two-year low after flagging weaker demand for heart device
• Negative Sentiment: Investor reaction has also been hurt by management’s lowered 2026 organic growth outlook, which suggests slower momentum than previously expected. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays decreased their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. BTIG Research reissued a “buy” rating and issued a $80.00 target price on shares of Boston Scientific in a report on Monday, May 18th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Finally, Stifel Nicolaus set a $75.00 target price on shares of Boston Scientific in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.46.

Boston Scientific Stock Performance

The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The business’s fifty day simple moving average is $60.69 and its 200-day simple moving average is $78.84. The firm has a market capitalization of $73.01 billion, a PE ratio of 20.55, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the firm posted $0.75 EPS. The company’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 3.37 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 9,800 shares of company stock valued at $554,012 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. State Street Corp grew its holdings in shares of Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors grew its holdings in shares of Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Norges Bank purchased a new position in shares of Boston Scientific in the fourth quarter valued at $2,199,395,000. Finally, Morgan Stanley grew its holdings in shares of Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.